Hearing impairment medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
mNo edit summary
Line 18: Line 18:
|[[Acyclovir]]
|[[Acyclovir]]
|}
|}
[[Otitis media]] in patients, [[antibiotics]] should be considered if symptoms do not improve in 3 days and/or severe symptoms.
[[antibiotics]] should be considered if symptoms of [[Otitis media]] in patients, do not improve in 3 days and/or they experience severe symptoms with high grade fever.


===[[Cerumen impaction]]===
===[[Cerumen impaction]]===
Line 62: Line 62:


*First-line treatment with oral [[steroids]] like [[Prednisone]] should be started within 14 days of symptoms onset. Prednisone has an [[Anti inflammatory medications|anti-inflammatory]] effect and must be used cautiously in [[diabetic]] patients because of its effect on blood glucose. The time to treatment is definite and emphasized.
*First-line treatment with oral [[steroids]] like [[Prednisone]] should be started within 14 days of symptoms onset. Prednisone has an [[Anti inflammatory medications|anti-inflammatory]] effect and must be used cautiously in [[diabetic]] patients because of its effect on blood glucose. The time to treatment is definite and emphasized.
*Another option for patients experiencing side effects with oral steroids is intratympanic steroids like [[dexamethasone]] but there's a risk for tympanic membrane perforation.
*Another option for patients experiencing side effects with oral steroids is intratympanic steroids injections like [[dexamethasone]] but there's a risk for tympanic membrane perforation.
*[[Hyperbaric medicine|Hyperbaric oxygen]] therapy remains an option but only when combined with steroid therapy for oral or intratympanic initial treatment.
*[[Hyperbaric medicine|Hyperbaric oxygen]] therapy remains an option but only when combined with steroid therapy for oral or intratympanic initial treatment.
*[[Antioxidants]] were removed from the list of treatments as they carry no clear-cut benefit.
*[[Antioxidants]] were removed from the list of treatments as they carry no clear-cut benefit.

Revision as of 16:59, 6 May 2021

Hearing impairment Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Social Impact

Future or Investigational Therapies

Case Studies

Case #1

Hearing impairment On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hearing impairment

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hearing impairment

CDC on Hearing impairment

Hearing impairment in the news

Blogs on Hearing impairment

Directions to Hospitals Treating Hearing impairment

Risk calculators and risk factors for Hearing impairment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

Medical therapy includes removal of impacted cerumen via irrigation, manually, cerumenolytics, and under microscopy. Sudden onset SNHL can be treated with a single dose of steroids.

Medical Therapy[1]

Medical treatment includes the use of antivirals, steroids, and antibiotics. Antivirals have been used in cases caused by viral infection.

Virus Medical Therapy
Congenital CMV infection Ganciclovir (administered intravenously)
HSV-1 Acyclovir

antibiotics should be considered if symptoms of Otitis media in patients, do not improve in 3 days and/or they experience severe symptoms with high grade fever.

Cerumen impaction

Method 1. Cerumenolytics[2]

  • 3-5 drops of cerumenolytics are used 3 times/day to decrease impaction by lubrication and softening of earwax (oil-based) and/or fragmentation of skin cells within cerumen (water-based). It is a cheap and effective way to remove wax with minimal side effects.
  • Cerumenolytics must be cautiously used in patients with tympanic membrane perforation, rupture, or any active infections of the ear canal and eardrum.
Water-based cerumenolytics Oil-based cerumenolytics
Acetic acid,
Mineral oil
Hydrogen peroxide,
Debrox
Cerumenex
Murine

Method 2. Irrigation

  • Aural irrigation with water in patients is another effective method for wax removal. Irrigation with water is avoided in diabetic patients or use acidifying solutions after water irrigation.

Method 3. Manual extraction

  • An otolaryngologist manually extracts wax from the ear canal under otoscopic observation. A Stenosed ear canal due to a history of radiations to the head and neck or any trauma to the head can complicate the procedure.

Method 4. Vacuum extraction

Method 5. Extraction under binocular microscopy

Idiopathic sudden sensorineural hearing loss:[3][4]

  • Sudden hearing loss is a serious symptom that often requires an urgent visit to the hospital.
  • Firstly address distinguishing sensorineural hearing loss from conductive hearing loss at the time of presentation with hearing loss in a hospital setting. It can be done through weber and/or Rinne test or audiometry.
  • First-line treatment with oral steroids like Prednisone should be started within 14 days of symptoms onset. Prednisone has an anti-inflammatory effect and must be used cautiously in diabetic patients because of its effect on blood glucose. The time to treatment is definite and emphasized.
  • Another option for patients experiencing side effects with oral steroids is intratympanic steroids injections like dexamethasone but there's a risk for tympanic membrane perforation.
  • Hyperbaric oxygen therapy remains an option but only when combined with steroid therapy for oral or intratympanic initial treatment.
  • Antioxidants were removed from the list of treatments as they carry no clear-cut benefit.
  • Follow-up audiometry at end of treatment and also within 6 months posttreatment is added to reassess any residual or reoccurrence of hearing loss.

Hearing Aids:

Hearing devices are either implantable or non-implantable. These devices include:

  • Conventional air-conduction hearing aids: The conventional air-conduction hearing aids are used with a microphone that converts sounds into electrical signals, returned to the ear as amplified sound. They are useful for patients with mild-to-severe hearing loss.
  • Bone-anchored hearing aids (BAHAs): BAHA devices incorporate a titanium plate that is surgically anchored to the skull on the hearing-impaired side, to directly stimulate the inner ear by conducting sound vibrations through the bone. Some of the indications for BAHA include severe conductive hearing loss, congenital ear canal atresia, SNHL, and difficulty wearing a conventional air-conduction aid with an ear fungal infection, due to recurrent ear infections.
  • Cochlear implants: The cochlear implant is a biomedical device that is surgically placed into the cochlea. It converts sound energy into an electrical signal, which is then conducted to the ganglion cells in the cochlea of inner ear through electrodes of device. This conduction eventually produces an auditory signal to the individual that allows the detection of sounds, especially speech sounds.

References

  1. Nieman CL, Oh ES (2020). "Hearing Loss". Ann Intern Med. 173 (11): ITC81–ITC96. doi:10.7326/AITC202012010. PMID 33253610 Check |pmid= value (help).
  2. Schwartz SR, Magit AE, Rosenfeld RM, Ballachanda BB, Hackell JM, Krouse HJ; et al. (2017). "Clinical Practice Guideline (Update): Earwax (Cerumen Impaction)". Otolaryngol Head Neck Surg. 156 (1_suppl): S1–S29. doi:10.1177/0194599816671491. PMID 28045591.
  3. Nieman CL, Oh ES (2020). "Hearing Loss". Ann Intern Med. 173 (11): ITC81–ITC96. doi:10.7326/AITC202012010. PMID 33253610 Check |pmid= value (help).
  4. Chandrasekhar SS, Tsai Do BS, Schwartz SR, Bontempo LJ, Faucett EA, Finestone SA; et al. (2019). "Clinical Practice Guideline: Sudden Hearing Loss (Update)". Otolaryngol Head Neck Surg. 161 (1_suppl): S1–S45. doi:10.1177/0194599819859885. PMID 31369359.